This interactive seminar will focus on human-relevant New Approach Methodologies(NAMs) and translational biomarkers can be integrated to increase prediction of humanoutcome, support better informed decisions and design smarter first-in-human and early clinical studies.

• Early de-risking with NAMS: How NAMs (3D microtissues, organoids, organ-on-chip and other in vitro systems) can help early safety decisions, identify mechanisms specific risks and derisk molecules while improving the human relevance of preclinical data
• Translational and predictive biomarkers: selecting the right patients, monitoring safety and target engagement, and reading early efficacy signals from first-in-human studies
• Turning early data into clinical decisions: integrating PK-PD modelling, NAM and biomarker data to design smarter early clinical studies

AGENDA

• 12:15 – Welcome and introduction (Biopôle and Evotec)
• 12:20 – De-risking early with NAMs – Paul Walker, Cyprotex-Evotec
• 12:35 – From Biomarkers to Better Decisions: Aiming for Precision Medicine – Elizabeth van der Kam, Evotec
• 12:50 – From early data to clinical and regulatory strategy – Paola Tocchetti, Evotec
• 13:05 – Q&A and panel discussion with all speakers
• 13:15 – Light lunch and networking
• 14:00-17:00 – 1:1 meetings with Evotec experts (on request)

TARGETED AUDIENCE

Biotech companies and start-ups at discovery, preclinical or early clinical stage working on all modalities (small molecules, proteins and antibodies, peptides, oligonucleotides/RNA, ADCs, cell and gene therapies and other novel modalities), across oncology, immunology, rare diseases and other therapeutic areas.

ABOUT EVOTEC

Evotec is a life science company driving innovation in drug discovery and development. Combining cutting-edge science, AI-driven innovation, and proprietary technologies such as PanOmics and iPSC, we accelerate the journey from concept to cure. With tailored partnering models, we serve Top 20 Pharma, biotechs, academia, and healthcare stakeholders.